Figure 6.
Simulated average plasma concentration time profile for a single 0.25 mg oral dose of repaglinide with and without 300 mg canagliflozin once daily in healthy subjects
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.